 <h1>Ocaliva Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>obeticholic acid</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about obeticholic acid. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ocaliva.</p><h2>In Summary</h2><p><b>Common side effects of Ocaliva include:</b> severe pruritus, eye pruritus, pruritic rash, pruritus, pruritus ani, skin rash, vulvovaginal pruritus, decreased hdl cholesterol, macular eruption, maculopapular rash, miliaria, papular rash, urticaria, and pruritus of ear.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to obeticholic acid: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Warning: Hepatic Decompensation and Failure in Incorrectly Dosed PBC Patients with Child-Pugh Class B or C or Decompensated CirrhosisIn postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when obeticholic acid was dosed more frequently than recommended.The recommended starting dosage of obeticholic acid is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior decompensation event.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, obeticholic acid (the active ingredient contained in Ocaliva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking obeticholic acid:</p><p>
<i>More common</i>
</p><ul>
<li>Fever</li>
<li>severe itching skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Chills</li>
<li>clay-colored stools</li>
<li>dark urine</li>
<li>dizziness</li>
<li>headache</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>rash</li>
<li>stomach pain and bloating</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of obeticholic acid may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>difficulty having a bowel movement</li>
<li>difficulty with moving</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
<li>rapid weight gain</li>
<li>sore throat</li>
<li>tingling of the hands or feet</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Skin rash, encrusted, scaly and oozing</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to obeticholic acid: oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects include pruritus, fatigue, and abdominal pain/discomfort.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Pruritus occurred most frequently in patients given 10 mg than in patients titrated to 10 mg and in those given placebo; these patients were more likely to develop pruritus within the first month.  Discontinuation due to pruritus was also more common in patients given 10 mg.</p>
<p></p>
<p>Severe pruritus includes skin eruptions, prurigo, pruritus, pruritus generalized, eye pruritus, ear pruritus, anal pruritus, vulvovaginal pruritus, and rash pruritus.</p>
<p></p>
<p>Rash includes urticaria, rash, rash macular/papular/maculopapular, heat rash, and urticaria cholinergic.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Pruritus (up to 70%), rash (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Eczema</p>
<p><b>Frequency not reported</b>: Cholinergic urticaria, generalized pruritus, heat rash, macular rash, maculopapular rash, papular rash, prurigo, pruritic rash, skin eruptions, urticaria<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 25%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia</p>
<p><b>Frequency not reported</b>: Asthenia, ear pruritus, tiredness<sup>[Ref]</sup></p><p>Fatigue includes fatigue, tiredness, and asthenia.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): High-density lipoprotein-cholesterol (HDL-C) reduction (up to 20%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Abdominal pain/discomfort includes upper/lower abdominal pain, abdominal pain, abdominal discomfort, abdominal tenderness, and gastrointestinal pain.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Abdominal pain/discomfort (up to 19%)</p>
<p><b>Common</b> (1% to 10%): Constipation, oropharyngeal pain</p>
<p><b>Frequency not reported</b>: Abdominal tenderness, anal pruritus, ascites, gastrointestinal pain, lower abdominal pain, new/worsening ascites, upper abdominal pain, variceal bleeding<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations, peripheral edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Dizziness includes dizziness, syncope, and presyncope.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Dizziness</p>
<p><b>Frequency not reported</b>: Hepatic encephalopathy, presyncope, syncope</p>
<p><b>Postmarketing reports</b>: New/worsening hepatic encephalopathy<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Thyroid function abnormality</p>
<p><b>Frequency not reported</b>: Decreased free thyroxine, hypothyroidism, increased blood thyroid stimulating hormone<sup>[Ref]</sup></p><p>Thyroid function abnormality includes thyroxine free decreased, blood thyroid stimulating hormone increased, and hypothyroidism.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Alkaline phosphatase (ALP) increased, arthralgia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatic decompensation, liver failure, liver-related adverse reactions</p>
<p><b>Postmarketing reports</b>: Increased direct bilirubin, increased total bilirubin, new onset cirrhosis, new/worsening jaundice<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vulvovaginal pruritus<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Eye pruritus<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc., New York, NY. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Ocaliva (obeticholic acid)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: miscellaneous GI agents</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ocaliva &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Primary Biliary Cholangitis </li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to obeticholic acid: oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects include pruritus, fatigue, and abdominal pain/discomfort.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Pruritus occurred most frequently in patients given 10 mg than in patients titrated to 10 mg and in those given placebo; these patients were more likely to develop pruritus within the first month.  Discontinuation due to pruritus was also more common in patients given 10 mg.</p><p></p><p>Severe pruritus includes skin eruptions, prurigo, pruritus, pruritus generalized, eye pruritus, ear pruritus, anal pruritus, vulvovaginal pruritus, and rash pruritus.</p><p></p><p>Rash includes urticaria, rash, rash macular/papular/maculopapular, heat rash, and urticaria cholinergic.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Pruritus (up to 70%), rash (up to 10%)</p><p><b>Common</b> (1% to 10%): Eczema</p><p><b>Frequency not reported</b>: Cholinergic urticaria, generalized pruritus, heat rash, macular rash, maculopapular rash, papular rash, prurigo, pruritic rash, skin eruptions, urticaria<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 25%)</p><p><b>Common</b> (1% to 10%): Pyrexia</p><p><b>Frequency not reported</b>: Asthenia, ear pruritus, tiredness<sup>[Ref]</sup></p><p>Fatigue includes fatigue, tiredness, and asthenia.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): High-density lipoprotein-cholesterol (HDL-C) reduction (up to 20%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Abdominal pain/discomfort includes upper/lower abdominal pain, abdominal pain, abdominal discomfort, abdominal tenderness, and gastrointestinal pain.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Abdominal pain/discomfort (up to 19%)</p><p><b>Common</b> (1% to 10%): Constipation, oropharyngeal pain</p><p><b>Frequency not reported</b>: Abdominal tenderness, anal pruritus, ascites, gastrointestinal pain, lower abdominal pain, new/worsening ascites, upper abdominal pain, variceal bleeding<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations, peripheral edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Dizziness includes dizziness, syncope, and presyncope.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Dizziness</p><p><b>Frequency not reported</b>: Hepatic encephalopathy, presyncope, syncope</p><p><b>Postmarketing reports</b>: New/worsening hepatic encephalopathy<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Thyroid function abnormality</p><p><b>Frequency not reported</b>: Decreased free thyroxine, hypothyroidism, increased blood thyroid stimulating hormone<sup>[Ref]</sup></p><p>Thyroid function abnormality includes thyroxine free decreased, blood thyroid stimulating hormone increased, and hypothyroidism.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Alkaline phosphatase (ALP) increased, arthralgia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatic decompensation, liver failure, liver-related adverse reactions</p><p><b>Postmarketing reports</b>: Increased direct bilirubin, increased total bilirubin, new onset cirrhosis, new/worsening jaundice<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vulvovaginal pruritus<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Eye pruritus<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc., New York, NY. </p><h2>More about Ocaliva (obeticholic acid)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: miscellaneous GI agents</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ocaliva &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Primary Biliary Cholangitis </li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>